In our latest episode, we delve into the world of space medicine to explore how drug crystallization in microgravity could revolutionize biologic drug administration. Joining us is Dr Katie King, CEO of BioOrbit, to discuss the science, challenges, and technological advancements that could make space-based drug production a reality.
Few alliances have impacted patient care as significantly as the Myeloproliferative Neoplasms Research Consortium (MPN-RC). Established in 2006, the MPN-RC is an international group dedicated to advancing research and developing innovative treatment strategies for myeloproliferative neoplasms (MPNs). In this episode, we speak with John Mascarenhas, MD, about the coalition's founding, operational mechanics and how their efforts have led to paradigm-shifting therapies in the field.
A recent review by Prof. Florence Pasquier and colleagues highlights the potential of olutasidenib, a selective, oral, small-molecule inhibitor of the mutant IDH1 enzyme, recently approved by the FDA as treatment option for patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with isocitrate dehydrogenase 1 (IDH1) mutations.
The International Society on Thrombosis and Haemostasis (ISTH) has issued an evidence-based clinical practice guideline aimed at revolutionizing the treatment landscape for congenital haemophilia A and B. Hemophilia, a rare bleeding disorder caused by deficiencies in blood coagulation factors, affects individuals worldwide and demands intricate management strategies.
The EHA 2024 congress has once again united top haematology experts from around the globe. This year's event featured plenty of innovations and developments, from novel therapies to cutting-edge genetic studies. In this article we provide an overview of the late-breaking abstracts presented at the meeting.
Researchers at Vanderbilt University Medical Center (VUMC) have highlighted promising results from a phase II clinical trial for a new treatment for sickle cell disease (SCD). Published in Blood, the study aimed to achieve an 80% two-year event-free survival rate following a specific bone marrow transplant (BMT) method. The international trial, led by Dr DeBaun and Dr Adetola Kassim, involved 32 children and 38 adults from five countries.
We’re looking forward to the EHA 2024 Hybrid Congress which is taking place in Madrid, between 13-16 June 2024. Promising attendees the opportunity to explore the latest advancements in haematology, including cutting-edge technologies, treatments, and products. The focus will encompass a ...
Watch leading experts Shaji Kumar and Rahma Warsame discuss the current and evolving treatment landscape in relapsed/refractory multiple myeloma, as well as key factors influencing treatment decisions.
Experts answer questions with in-depth advice on the current clinical landscape and how new guidelines might impact regional clinical practice. Useful tips below will show how to navigate the activity.
Three experts consider unmet needs in chronic myeloid leukaemia and how new and emerging treatments may help address them.
Two specialists in chronic myeloid leukaemia (CML) discuss the mechanisms of action and latest data for current and emerging treatments and how they may impact the management of CML after two prior lines of therapy.
Watch a leading haematologist, a primary care physician and a patient with paroxysmal nocturnal haemoglobinuria (PNH) share their perspectives on the clinical challenges associated with PNH.
Three experts consider the potential of immune-based strategies to treat MDS and AML.
Watch this two-part activity exploring recent developments in the treatment of higher-risk MDS and newly diagnosed AML. Filmed following the EHA 2022 Hybrid Congress.
Watch this two-part activity exploring recent data on current and emerging treatments for CML. Filmed following the EHA Hybrid Conference 2022.
Watch chronic myeloid leukaemia (CML) specialists within a multidisciplinary team, plus a CML patient advocate, discuss the later-line management of CML.
Watch this two-part activity exploring recent data on new and emerging treatments for patients with higher-risk MDS and newly diagnosed AML, filmed following the ASH 2021 Annual Meeting & Exposition.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.